Asana BioSciences Relocates Operations To Lawrenceville, New Jersey
08/24/2016
“This move was necessary to further our vision of building an oncology-focused biopharmaceutical company,” said Sandeep Gupta, Ph.D., president and chief executive officer of Asana BioSciences. “As we continue to expand and grow, our new Princeton area location makes it ideal for us to attract key scientific and medical talent within the Central New Jersey and Philadelphia life sciences corridor.”
According to company officials, Asana continues to advance its portfolio of differentiated targeted therapies to help address major unmet medical needs, including a novel CYP17 inhibitor for prostate cancer and a dual Syk/JAK inhibitor for non-Hodgkin’s lymphoma that are in phase I/II clinical trials.
Asana BioSciences, an independent member of The Amneal Alliance of companies, is a research and development company, specializing in the discovery and development of novel drug candidates, including an antibody-drug conjugate. Asana’s portfolio consists of multiple early-stage development candidates in a variety of therapeutic areas, including oncology, pain and inflammation, among others. Over the past year, it has been adding key talent to its team, including the appointment of a chief medical officer and expansion of its scientific advisory board.
Project Announcements
Momentous Expands Summit County, Utah, Operations
12/21/2025
Stryker Expands Salt Lake County, Utah, Operations
12/21/2025
Portal Space Systems Expands Bothell, Washington, Operations
12/21/2025
TerraForge Biocarbon Solutions Plans Magnolia, Mississippi, Operations
12/20/2025
Coastal Ready Mix Plans Conway, South Carolina, Production Operations
12/20/2025
PRET Advanced Materials Expands Johnsonville, South Carolina, Manufacturing Operations
12/19/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
America’s Aerospace Reboot
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025